• Skip to main content
  • Skip to footer

Life Sciences British Columbia

  • Newsletters |
  • Members Area |
  • Contact
  • SearchSearch
  • About
    • Board of Directors
    • Management
    • Vision & Mission
  • Awards
  • Membership
    • Sponsors
    • Members Directory
    • Members Area
    • Membership Benefits
    • Membership Discounts
    • Members Services
    • Members Map
    • Become a Member
  • Events
    • Calendar
    • Webinars
    • Past Events
      • 2023 Events
      • 2022 Events
      • 2021 Events
      • 2020 Events
      • 2019 Events
      • 2018 Events
  • News
    • All News
    • Member News
    • Industry News
    • LSBC in The News
    • Publications
    • BC Labour Market Study
  • Resources
    • All Resources
    • Grants and Funding
      • Funding Competitions
      • Wage Subsidies
    • Academic Institutions
    • Government
      • Federal
      • Provincial and Municipal
    • Association Partners
    • Programs
    • Volunteering
  • Jobs
    • Job Board
    • Post a Job
    • Career Events
  • Contact Us
  • Login

Aurinia Pharma U.S., Inc.

Member Profile

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company introduced and is commercializing the first U.S. FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

Sector
Biotechnology, Therapeutics
Area of Expertise
  • Autoimmune Diseases
  • Therapeutics
Company Stage Commercial Stage, Public Company
Employees outside Canada 263 employees
Stock Ticker AUP - TSE

Member Profile

Biotechnology, Therapeutics

Aurinia Pharma U.S., Inc.

Silver Sponsor

aurinia logo black text
  • Website www.auriniapharma.com
  • Phone +1 (250) 744 2487
  • Address
    #1203 – 4464 Markham Street
    Victoria, BC
    V8Z 7X8
  • Leadership Contact
    Peter Greenleaf, CEO & Director
    Follow us:
  • Twitter
  • Facebook
  • LinkedIn
  • News
  • Jobs

May 9, 2023

Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® (voclosporin) AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference

May 3, 2023

Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® (Voclosporin) for Adults with Active Lupus Nephritis

April 11, 2023

Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office

April 5, 2023

Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial

January 24, 2023

Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office

No current content.

  • Twitter
  • Linkedin
Tweets by Aurinia Pharma U.S., Inc.
Connect with us LinkedIn

© 2023 Life Sciences BC  |  Privacy Policy

  • Current Jobs
  • Event Calendar
  • All News
  • Member Directory
    Connect with us
  • LinkedIn
  • Twitter
  • Facebook
  • Instagram
Contact Us